bintrafusp alfa (M7824) / EMD Serono  >>  Phase 1
Welcome,         Profile    Billing    Logout  

13 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bintrafusp alfa (M7824) / EMD Serono
NCT04296942 / 2013-000783-29: BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

Terminated
1b
1
US
Brachyury-TRICOM, Entinostat, SNDX-275, M7824, Bintrafusp alfa, Ado-trastuzumab emtansine, T-DM1
National Cancer Institute (NCI)
Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer, Hormone Receptor Negative Breast Cancer, Metastatic Breast Cancer
10/21
10/21
RACHEL1, NCT03524170: Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Completed
1
24
US
Bintrafusp Alfa, Anti-PDL1/TGFb Trap MSB0011359C, M7824, MSB0011359C, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation
M.D. Anderson Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
02/22
02/22
NCT04756505: Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

Withdrawn
1
0
NA
Bintrafusp Alfa, Anti-PDL1/TGFb Trap MSB0011359C, M7824, MSB0011359C, Immunocytokine NHS-IL12, M-9241, M9241, NHS-IL-12, NHS-IL12, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
M.D. Anderson Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic HER2 Negative Breast Adenocarcinoma, Prognostic Stage IV Breast Cancer AJCC v8
02/22
02/22
NCT02699515: MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors

Completed
1
114
Japan, RoW
MSB0011359C, M7824
Merck KGaA, Darmstadt, Germany
Solid Tumors
02/22
02/22
EMR 200647-001, NCT02517398: MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

Checkmark P1b data for advanced NSCLC cohorts at ASCO 2018 [screenshot]
Jun 2018 - Jun 2018: P1b data for advanced NSCLC cohorts at ASCO 2018 [screenshot]
Checkmark Data in HPV associated cancers at ASCO 2018 [screenshot]
Jun 2018 - Jun 2018: Data in HPV associated cancers at ASCO 2018 [screenshot]
Completed
1
600
Europe, Canada, Japan, US, RoW
MSB0011359C, M7824
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Solid Tumors
05/22
05/22
INTR@PID 046, NCT04551950: Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer

Completed
1
25
Europe, Japan, US
M7824, Bintrafusp alfa, Carboplatin, Paclitaxel, Bevacizumab, Cisplatin, Radiotherapy
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Cervical Cancer
06/22
06/22
NCT04349280: A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer

Hourglass Jul 2022 - Sep 2022 : Data from trial for 2L urothelial cancer
Terminated
1
25
Europe, Canada, US
Bintrafusp alfa
GlaxoSmithKline, Merck KGaA, Darmstadt, Germany
Neoplasms
08/22
08/22
NCT03579472: M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

Terminated
1
38
US
Bintrafusp Alfa, Anti-PDL1/TGFb Trap MSB0011359C, M7824, MSB0011359C, Eribulin Mesylate, B1939 Mesylate, E7389, ER-086526, Halaven, Halichondrin B Analog
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
09/22
09/22
NCT04457778: First in Human Study of M6223

Checkmark Data from trial in combination with M6223 for advanced solid tumors
Oct 2022 - Oct 2022: Data from trial in combination with M6223 for advanced solid tumors
Completed
1
58
Canada, US
M6223, Bintrafusp alfa
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Metastatic Solid Tumors
06/23
06/23
INDUCE-1, NCT02723955: Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors

Completed
1
829
Europe, Canada, Japan, US, RoW
feladilimab (GSK3359609), GSK3174998, Pembrolizumab, Docetaxel, Pemetrexed, Paclitaxel plus Carboplatin, Gemcitabine plus Carboplatin, Fluorouracil (5-FU) plus carboplatin or cisplatin, Dostarlimab, Cobolimab, Bintrafusp alfa
GlaxoSmithKline, Merck Sharp & Dohme LLC
Neoplasms
07/23
07/23
20-C-0012, NCT04235777: Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

Recruiting
1
66
US
M7824, M9241, Stereotactic body radiation therapy (SBRT)
National Cancer Institute (NCI)
Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms, Urogenital Cancer
12/24
12/24
NCI-2018-01184, NCT03620201: M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer

Active, not recruiting
1
20
US
Bintrafusp Alfa, Anti-PDL1/TGFb Trap MSB0011359C, M7824, MSB0011359C
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
12/24
12/24
NCT04708067: Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

Active, not recruiting
1
15
US
Bintrafusp Alfa, Anti-PDL1/TGFb Trap MSB0011359C, M7824, MSB0011359C, Biopsy, BIOPSY_TYPE, Bx, Hypofractionated Radiation Therapy, Hypofractionated Radiotherapy, hypofractionation
M.D. Anderson Cancer Center
Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
02/27
02/27

Download Options